Public, Clinical Stage, Pharmaceutical company sought to expand their Board of Directors

July 25, 2022

Moleculin Biotech, Inc. is a public clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company‚Äôs lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. With a need to add…

Read More

$200m Series B ADC Biotech in search of CMO pre IPO

September 28, 2021

Pyxis Oncology are an exciting Boston based biotech working on antibody drug conjugates and monoclonal antibodies to treat a range of cancer indications. They had raised around $200m from top tier investors including RA Capital, Pfizer Ventures, Longwood Fund, Ipsen Ventures, Perceptive Advisors, BVF Partners and more. Approaching their IPO date with no CMO on…

Read More